中文网站
Recently, the Bigfish FC-96G Sequence Gene Amplifier has completed installation and acceptance testing at multiple provincial and municipal medical institutions, including several Class A tertiary hospitals and regional testing centres. The product has garnered unanimous praise from medical laboratory professionals for its outstanding performance and superior after-sales service.
The FC-96G/48N is a gene amplification instrument model designed by Bigfish specifically for the medical market, having obtained a medical device registration certificate. It features high temperature precision, rapid heating and cooling rates, and excellent module temperature uniformity, providing a stable and reliable environment for gene amplification experiments. Equipped with a 10.1-inch colour touchscreen and industrial-grade operating system, the instrument supports extended continuous operation and offers multiple file storage options for convenient programme preservation and transfer. Its user-friendly interface significantly reduces learning curves and operational costs, making it suitable for laboratory personnel across all levels of healthcare institutions.
Moreover, over the years, Bigfish's nucleic acid extraction systems and quantitative fluorescent PCR instruments have been extensively deployed across numerous medical institutions both domestically and internationally. These products are exported to dozens of countries and regions spanning Europe, America, and Southeast Asia, earning a strong reputation in the global marketplace. Their widespread adoption worldwide has enabled Bigfish to accumulate substantial clinical experience and cultivate an excellent market reputation. Bigfish's comprehensive product portfolio has evolved into a complete molecular diagnostics solution, providing all-encompassing technical support to healthcare institutions at every level.
As the nation continues advancing regional medical centre development and grassroots healthcare capacity enhancement initiatives, Bigfish will further increase its R&D investment. Leveraging its extensive domestic and international market experience, the company will deliver superior products and services to medical institutions, contributing to the Healthy China initiative and enabling Chinese-manufactured medical equipment to better serve global public health endeavours.
Post time: Sep-25-2025
Privacy settings